Emerging Therapies in Prostate Cancer

For High-Definition, Click

Raoul D. Concepcion, MD, introduces the topic of emerging therapies in patients with castration-resistant prostate cancer. Currently, in the docetaxel failure state, cabazitaxel, abiraterone, and enzalutamide are approved.

Concepcion highlights several key agents in phase III clinical trials. Alpharadin or radium-223 is an alpha radiopharmaceutical that has a narrow depth of penetration but has a survival benefit alone as well as response for pain relief and reduction of skeletal-related events.

Concepcion also mentions Oteronel or TAK-700, an oral agent, and Aragon or 509, an androgen signaling inhibitor.